Abstract: The ubiquitin ligase, RNF5, regulates the gut microbiota composition and influences the immune checkpoint response to tumors. RNF5 deficient animals exhibit significant inhibition of tumor development as well as an altered gut microbiota composition. Methods of treating cancer by administering to a subject one or more selected bacterial species and/or one or more prebiotics that promote the growth of one or more selected bacterial species are disclosed. Also disclosed are methods of treating cancer by administering to a subject one or more selected bacterial species and/or one or more prebiotics that promote the growth of one or more selected bacterial species in combination with one or more anti-cancer agents.

Abstract: The ubiquitin ligase, RNF5, regulates the gut microbiota composition and influences the immune checkpoint response to tumors. RNF5 deficient animals exhibit significant inhibition of tumor development as well as an altered gut microbiota composition. Methods of treating cancer by administering to a subject one or more selected bacterial species and/or one or more prebiotics that promote the growth of one or more selected bacterial species are disclosed. Also disclosed are methods of treating cancer by administering to a subject one or more selected bacterial species and/or one or more prebiotics that promote the growth of one or more selected bacterial species in combination with one or more anti-cancer agents.

Abstract: The present invention relates to the seminal discovery that P-selectin glycoprotein ligand-1 (PSGL-1) modulates the immune system and immune responses. Specifically, the present invention provides PSGL-1 agonists and antagonists which increase the survival of multifunctional T cells and viral clearance. The present invention further provides methods of treating infectious diseases, cancer and immune and inflammatory diseases and disorders using a PSGL-1 modulator.

Abstract: The present invention relates to the seminal discovery that P-selectin glycoprotein ligand-1 (PSGL-1) modulates the immune system and immune responses. Specifically, the present invention provides PSGL-1 agonists and antagonists which increase the survival of multifunctional T cells and viral clearance. The present invention further provides methods of treating infectious diseases, cancer and immune and inflammatory diseases and disorders using a PSGL-1 modulator.

Abstract: The present invention relates to the seminal discovery that P-selectin glycoprotein ligand-1 (PSGL-1) modulates the immune system and immune responses. Specifically, the present invention provides PSGL-1 agonists and antagonists which increase the survival of multifunctional T cells and viral clearance. The present invention further provides methods of treating infectious diseases, cancer and immune and inflammatory diseases and disorders using a PSGL-1 modulator.

Abstract: The ubiquitin ligase, RNF5, regulates the gut microbiota composition and influences the immune checkpoint response to tumors. RNF5 deficient animals exhibit significant inhibition of tumor development as well as an altered gut microbiota composition. Methods of treating cancer by administering to a subject one or more selected bacterial species and/or one or more prebiotics that promote the growth of one or more selected bacterial species are disclosed. Also disclosed are methods of treating cancer by administering to a subject one or more selected bacterial species and/or one or more prebiotics that promote the growth of one or more selected bacterial species in combination with one or more anti-cancer agents.

Abstract: The present invention relates to the seminal discovery that P-selectin glycoprotein ligand-1 (PSGL-1) modulates the immune system and immune responses. Specifically, the present invention provides PSGL-1 agonists and antagonists which increase the survival of multifunctional T cells and viral clearance. The present invention further provides methods of treating infectious diseases, cancer and immune and inflammatory diseases and disorders using a PSGL-1 modulator.

Abstract: The present invention provides a process for absorbing solar energy and, simultaneously having a continuous control of the light admission making it possible to install the device in external openings of buildings and equipment, such as windows, shutters or skylights. The system comprises two frames which support plates of transparent material, between which it is possible to introduce a colourful solution coming from an external reservoir. Both frames are interconnected through a flexible membrane which allows the plates to be pushed against each other, making the window transparent, or pushed away interposing the colourful solution, which will make the window uniform and gradually translucent or opaque. The said liquid comes from a reservoir and the access to the gap between the plates through is obtained by means of a channel that separates the two frames, allowing the liquid to flow evenly into the whole surface, thus being a homogenous and adjustable darkening obtainable.

Abstract: The present invention provides a process for absorbing solar energy and, simultaneously having a continuous control of the light admission making it possible to install the device in external openings of buildings and equipment, such as windows, shutters or skylights. The system comprises two frames which support plates of transparent material, between which it is possible to introduce a colourful solution coming from an external reservoir. Both frames are interconnected through a flexible membrane which allows the plates to be pushed against each other, making the window transparent, or pushed away interposing the colourful solution, which will make the window uniform and gradually translucent or opaque. The said liquid comes from a reservoir and the access to the gap between the plates through is obtained by means of a channel that separates the two frames, allowing the liquid to flow evenly into the whole surface, thus being a homogenous and adjustable darkening obtainable.